Of some interest was the fact that there was no update on the leadership roles. Its self-apparent, however, that someone is making executive decisions.
The leadership vacuum doesn't appear to be unsettling the progression of the science, negotiations with Pharma or even the share price (despite consistent selling). Presumably, as pointed out by Lionhearted, "Richard's chair was not cold for longer than a couple of weeks".
If anything as far as the science is concerned, there appears to be a sharp focus in building towards pre-clinical or as ds makes the point "seems like more progress or information in 3-4 months than the 6 months prior".
Left field may have a lot to offer. Watch out for a fast ball from the FPP delivery platform. Given that peptide delivery is not new but problematic because of adverse side effects, there appears to be positive signs in relation to the safety of FPP's.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)